Detailed price information for ME Therapeutics Holdings Inc. (METX-CN) from The Globe and Mail including charting and trades.
Programmable circRNA platform achieves near-complete B cell depletion in non-human primates using targeted in vivo CAR-T deliveryBOSTON--(BUSINESS WIRE)--Strand Therapeutics, a clinical-stage ...
Findings show that impaired autophagy leads to muscle degeneration, inflammation, and mitochondrial defects, while ...
A series of recent physiology studies span from rare disease mechanisms to space-based biomedical advances. Findings include a new mouse model for myofibrillar myopathy type 6 that identifies ...
Researchers at the University Hospital Bonn have developed a humanized mouse model for myofibrillar myopathy type 6 (MFM6), revealing that impaired autophagy driven by a defective BAG3 protein leads ...
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically shortened life expectancy due to a disruption in muscle protein regulation.
The field of cancer immunotherapy and immunology is rapidly reshaping modern oncology, yet the translational gap between mechanistic discoveries and durable ...
Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based ...
11d
New clues to hepatitis B species restriction could help build a novel model for studying infection
Some 254 million people live with a chronic hepatitis B (HBV) infection that is often asymptomatic for decades, only to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results